Sequential Left Ventricular Assist Device (LVAD) Unloading and Conditioning to Induce Sustained Cardiac Recovery
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Change in Left Ventricular Ejection Fraction (LVEF)
研究概览
简要总结
The purpose of this study is to investigate the potential recovery of heart function in end-stage heart failure patients supported with a Left Ventricular Assist Device (LVAD) through applying a myocardial conditioning protocol. During myocardial conditioning, LVAD speed is reduced gradually in order to increase the work load of the heart. Multiple previous studies have shown that interventions like this may improve heart function and give patients the opportunity for a better quality of life.
详细描述
Heart failure can be caused by various disorders, such as myocardial infarction, hypertension, viral infection, exposure to toxins, chemotherapy, or genetically transmitted muscular diseases. Regardless of the etiology, these disorders initiate ventricular remodeling, an adaptive, compensatory process which becomes progressively maladaptive and the cause of functional and clinical deterioration, eventually leading to heart failure. Local and systemic compensatory responses that initially allow surviving muscle to maintain hemodynamic function continue over time and due to this persistent compensatory over-activity the initially unaffected myocardium becomes dysfunctional. These compensatory responses to an abnormal cardiac load or myocardial injury involve several pathophysiological adaptations in the cardiac structure at the genetic, molecular, cellular, and tissue levels. Furthermore, left ventricular pressure and volume overload has shown to alter metabolic substrate utilization, decrease mitochondrial function and reduce energy production in the failing heart.
Mechanical circulatory support with LVAD has become a standard bridge to cardiac transplantation, and has also been approved in the United States as permanent (destination) therapy for selected patients presenting with end-stage heart failure. Clinical experience with LVAD support has shown that it can reverse the complex process of chronic left ventricular remodeling to a point where a subset of patients could be weaned from the device after restoration of basic cardiac function. LVAD-induced mechanical unloading of the failing heart leads to reduced mitochondrial density, structure and function, and interventions that enhance mitochondrial biogenesis, function and structure, such as controlled cardiac reloading may enhance LVAD-induced myocardial reverse remodeling and cardiac recovery. This study is designed to investigate gradual reduction in LVAD speed within the range defined by the assist device manufacturer's manual as appropriate for regular clinic use, to determine the effect on reverse remodeling and myocardial recovery in end-stage heart failure patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with heart failure undergoing LVAD implantation as a bridge to transplant
- •Enrolled in the Effects of Mechanical Unloading on Myocardial Function and Structure study (IRB 30622)
排除标准
- •Neither the subject nor the subject's representative is willing to provide written consent for participation
- •Subjects with adverse events leading to hospitalization during the optimum unloading phase are excluded from participation in the controlled reloading phase
研究组 & 干预措施
Controlled Cardiac Reloading
Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
干预措施: Controlled Cardiac Reloading through LVAD Speed Adjustment (Device)
结局指标
主要结局
Change in Left Ventricular Ejection Fraction (LVEF)
时间窗: Baseline (prior to LVAD implantation) and 12 months post-LVAD implantation, or at time of LVAD explantation/heart transplant
LVEF is measured by echocardiography. The average change in LVEF from baseline to 12 months or transplant in the study participant arm will be compared to results from an historical control group.
次要结局
- Change in Left Ventricular End Diastolic Diameter (LVEDD)(Baseline (prior to LVAD implantation) and 12 months post-LVAD implantation, or at time of LVAD explantation/heart transplant)
- Change in Left Ventricular End Systolic Diameter (LVESD)(Baseline (prior to LVAD implantation) and 12 months post-LVAD implantation, or at time of LVAD explantation/heart transplant)
- Change in heart tissue Pyruvate levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Lactic Acid levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in Left Ventricular End Diastolic Volume (LVEDV)(Baseline (prior to LVAD implantation) and 12 months post-LVAD implantation, or at time of LVAD explantation/heart transplant)
- Change in Left Ventricular End Systolic Volume (LVESV)(Baseline (prior to LVAD implantation) and 12 months post-LVAD implantation, or at time of LVAD explantation/heart transplant)
- Change in heart tissue Glucose 1-phosphate levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Glucose Transporter 4 (GLUT4) messenger ribonucleic acid (mRNA) levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Mitochondrial Pyruvate Carrier 1 (MPC1) levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Mitochondrial Pyruvate Carrier 2 (MPC2) levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Glucose 6-phosphate levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Glucose Transporter 1 (GLUT1) levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Acetyl Coenzyme A levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Glucose Transporter 1 (GLUT1) messenger ribonucleic acid (mRNA) levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Mitochondrial Density(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
- Change in heart tissue Glucose Transporter 4 (GLUT4) levels(Baseline (LVAD implantation) and at time of LVAD explantation/heart transplantation (up to 12 months))
研究者
STAVROS G DRAKOS
Principal Investigator
University of Utah